Medical Ethics Advisor – May 1, 2017
May 1, 2017
View Issues
-
Committee Says Human Genome Editing Ethically Permissible — Under Certain Conditions
Stringent oversight might be necessary in order for heritable germline editing clinical trials to be conducted, according to a new report indicating use of the technique could be ethically permissible, but only for treating or preventing serious diseases.
-
Study: Scientifically Unproven Marketing Claims Very Common on Websites
Marketing claims on websites of complementary and alternative medicine therapies practitioners regarding allergy and asthma often included interventions that were not scientifically supported, according to a new study.
-
Updated Common Rule: ‘Massive Improvement’ For Human Subjects Research
The long-awaited updated Common Rule for federal regulations for ethical conduct of human subjects research is quite different from what was initially proposed.
-
NIH Policy on Review of Multicenter Studies: ‘One Size Fits All’
A new National Institutes of Health policy mandates that all domestic sites participating in multicenter research studies use a single institutional review board.
-
Research Misconduct Rarely Reported by Authors of Systematic Reviews
Research misconduct — not publishing completed research, duplicate publications, or selective reporting of outcomes — sometimes is identified by authors of systematic reviews, but is rarely reported, found a recent study.
-
It’s Not Just MDs: Patient Advocacy Organizations Have Industry Ties, Too
Recent studies have revealed surprising financial ties of patient advocacy organizations: the vast majority receive financial support from drug, device, and biotechnology companies.
-
Study Sheds Light on Surrogates’ Decision-making
It comes as no surprise to anyone with experience caring for patients at the end of life that family members often have difficulty predicting a patient’s desire for life-sustaining treatments. Reasons for this are less well-understood, however.